Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWI094)

• Drug Name: YM-43611 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Psychotic disorder	6A20-6A25	Terminated	[1]

• Cross-matching ID:
  PubChem CID: 9802631
  TTD Drug ID: DMWI094

Molecule-Related Drug Atlas

Drug(s) Targeting Dopamine D3 receptor (D3R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cariprazine	DMJYDVK	Bipolar disorder	6A60	Approved	[3]
Pramipexole	DMNMW9R	Parkinson disease	8A00.0	Approved	[4]
Ropinirole	DMA6S1D	Parkinson disease	8A00.0	Approved	[4]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[5]
P2B-001	DM9PVHX	Parkinson disease	8A00.0	Phase 3	[6]
RP5063	DMKUE8O	Schizophrenia	6A20	Phase 2	[7]
ONC201	DMM5SCF	Endometrial cancer	2C76	Phase 2	[8]
TAK-906	DMBQD9H	Diabetic gastroparesis	DA41.00	Phase 2	[9]
GSK598809	DMGU05N	Drug abuse	6C4G.1Z	Phase 2	[10]
GSK618334	DMJPXZ4	Drug abuse	6C4G.1Z	Phase 1	[10]

Drug(s) Targeting Dopamine D4 receptor (D4R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[4]
Phenyltoloxamine	DMKAEQW	Allergy	4A80-4A85	Approved	[11]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[5]
RP5063	DMKUE8O	Schizophrenia	6A20	Phase 2	[7]
L-745,870	DMTGR25	Psychotic disorder	6A20-6A25	Phase 2	[12]
NGD 94-1	DMM1Y8F	Schizophrenia	6A20	Phase 1	[13]
ABT-724	DMDQVY4	Erectile dysfunction	HA01.1	Discontinued in Phase 2	[14]
Lu-35138	DMQ7A35	Psychotic disorder	6A20-6A25	Discontinued in Phase 2	[15]
NGD-94-4	DMZ9WLO	Schizophrenia	6A20	Discontinued in Phase 1	[16]
PD-165167	DMD0GB4	Schizophrenia	6A20	Preclinical	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D3 receptor (D3R)	TT4C8EA	DRD3_HUMAN	Modulator	[2]
Dopamine D4 receptor (D4R)	TTE0A2F	DRD4_HUMAN	Modulator	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005975)
• [2] Effects of YM-43611, a novel dopamine D2-like receptor antagonist, on immediate early gene expression in the rat forebrain. Neuropsychopharmacology. 1997 Jul;17(1):27-33.
• [3] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
• [6] Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18.
• [10] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [11] Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
• [12] Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI. Psychopharmacology (Berl). 2009 Apr;203(2):265-77.
• [13] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [14] Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc Natl Acad Sci U S A. 2004 April 27; 101(17): 6758-6763.
• [15] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014237)
• [16] I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor. J Pharmacol Exp Ther. 1997 Aug;282(2):1011-9.